CEO Total Pay
$20.1M
FY2022 Summary Compensation, well above median
FY2022 SEC EDGAR DEF 14A
Horizon Therapeutics Public Ltd Co CEO pay ratio
The CEO earned $20.1M in FY2022 against median worker pay of $264,751 · Chemicals & Pharmaceuticals.
- State
- L2
- Filing date
- 2023-06-30
- Industry
- Chemicals & Pharmaceuticals
- Fiscal year
- FY2022
Data updated August 2026
Subscribe to Horizon Therapeutics Public Ltd Co CEO pay filing updates (RSS)
CEO-to-worker pay ratio
76:1
Moderate (Scale: 0–1000:1)
CEO pay
$20.1M
Median worker
$264,751
Latest filing FY2022. This company's newest DEF 14A on file is for FY2022, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.
Answer first
Horizon Therapeutics Public Ltd Co reported a 76:1 CEO-to-worker pay ratio in FY2022 - above the Chemicals & Pharmaceuticals median of 42:1 across 168 filers.
Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.
- Pay ratio
- 76:1
- FY2022 disclosed
- CEO total
- $20.1M
- Summary Compensation Table total
- Median worker
- $264,751
- Dodd-Frank median employee
Ratio bands among Chemicals & Pharmaceuticals peers
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
CEO Compensation Breakdown, FY2022
A component-level pay breakdown is not reported in Horizon Therapeutics Public Ltd Co's structured SEC pay-ratio disclosure. See our methodology →
Filing-year trail · Horizon Therapeutics Public Ltd Co
Complete DEF 14A pay-ratio filings for this CIK across FY2021–2022. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).
- Latest ratio
- 76:1
- FY2022
- vs prior FY
- +4:1
- from FY2021 72:1
- CEO $ YoY
- -6.3%
- $20.1M latest
- Filings shown
- 2
- FY2021–2022
| FY | CEO pay | Δ pay | Median worker | Pay ratio | Δ ratio |
|---|---|---|---|---|---|
| 2021 | $21.5M | - | $298,200 | 72:1 | - |
| 2022 | $20.1M | -6.3% | $264,751 | 76:1 | +4:1 |
Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1492426, FY2021–2022. Adjacent-year deltas only.
Industry Comparison - Chemicals & Pharmaceuticals
This Company's Ratio
76:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$20.1M
Companies in Industry
168
vs. Industry Median
Above
Horizon Therapeutics Public Ltd Co: MID · PEAK pay ratio
Horizon Therapeutics Public Ltd Co disclosed 76:1 CEO-to-worker pay and $20.1M CEO total in FY2022. the CEO earned 76× the median employee ($264,751) in FY2022.
Median employee $264,751 (ELITE-MED); MID · PEAK stamps put about 76 median-wage years per CEO year.
Pay Ratio
76:1
Near industry median
What FY2022 shows for Horizon Therapeutics Public Ltd Co
Horizon Therapeutics Public Ltd Co disclosed 76:1 CEO-to-worker pay and $20.1M CEO total in FY2022. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Horizon Therapeutics Public Ltd Co's $20.1M CEO total is above the $7.9M industry median CEO pay.
Horizon Therapeutics Public Ltd Co stamps MID · PEAK · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.
Key Data, FY2022
- Total Compensation
- $20.1M
- Median Employee Pay
- $264,751
- Pay Ratio
- 76:1
- Filing Date
- 2023-06-30
Company Info
- CIK
- 1492426
- Industry
- Chemicals & Pharmaceuticals
- SIC Code
- 2834
- State
- L2
SEC EDGAR DEF 14A for CIK 1492426, FY2022. Informational only, not investment advice. Verify on EDGAR.
Read our methodology - how this data is sourced, computed, and verified. Horizon Therapeutics Public Ltd Co disclosed 76:1 CEO-to-worker pay and $20.1M CEO total in FY2022.
Read with Horizon Therapeutics Public Ltd Co
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MID · PEAK · ELITE-MED.
Prudential Financial Inc · PEAK
ABS(ceo_total_comp) peer at $20.1M (Δ $15K lighter vs Horizon Therapeutics Public Ltd Co); MID · ELITE-MED vs this page's MID · PEAK · ELITE-MED.
RingCentral, Inc. · PEAK
ABS(ceo_total_comp) peer at $20.2M (Δ $69K heavier vs Horizon Therapeutics Public Ltd Co); STEEP · ELITE-MED vs this page's MID · PEAK · ELITE-MED.
Danaher Corp /de/ · PEAK
ABS(ceo_total_comp) peer at $20.2M (Δ $87K heavier vs Horizon Therapeutics Public Ltd Co); HIGH · PAR-MED vs this page's MID · PEAK · ELITE-MED.
Zai Lab Ltd · PEAK
ABS(ceo_total_comp) peer at $20.2M (Δ $91K heavier vs Horizon Therapeutics Public Ltd Co); PARITY · HIGH-MED vs this page's MID · PEAK · ELITE-MED.
Chemicals & Pharmaceuticals benchmark
Horizon Therapeutics Public Ltd Co stamps MID · PEAK · ELITE-MED inside SIC 28 - open the industry median board after the ABS peers.
Pay-ratio rankings · MID
See where MID · PEAK packages sit on the national leaderboard after reading Horizon Therapeutics Public Ltd Co.
Comp structure · PEAK
Horizon Therapeutics Public Ltd Co's PEAK CEO total is equity-sensitive - read what grant-date fair value does and does not mean.
Data sourced from SEC EDGAR DEF 14A for Horizon Therapeutics Public Ltd Co (CIK 1492426), FY2022. See our methodology. Aggregated by PlainCEOPay as of August 2026.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.